

Docket No.: 05986/100M536-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Thomas Wisniewski et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: MUCOSAL IMMUNIZATION TO PREVENT
PRION INFECTION

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

10/558276

IAP15 Rec'd PCT/PTO 18 NOV 2005

Application No.: Not Yet Assigned

2

Docket No.: 05986/100M536-US1


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: November 18, 2005

Respectfully submitted,

By  *Eryn Brassow*
(53970)

Paul M. Zagar

Registration No.: 52,392

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

1015 Rec'd 10/10/00 18 NOV 2005

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned 10/558 276
				Filing Date	Concurrently Herewith
				First Named Inventor	Thomas Wisniewski
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	5	Attorney Docket Number	05986/100M536-US 1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-6,440,423	08-27-2002	Clements et al.	
	AB*	US-6,436,407	08-20-2002	Clements et al.	
	AC*	US-6,019,982	02-01-2000	Clements et al.	
	AD*	US-5,843,446	12-01-1998	Ladd et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 03/045128	06-05-2003	FRANGIONE, Blas		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Jackson and Collinge, Mol Pathol. 2001;54:393-399	
	CB	Gajdusek and Zigas, N. Eng. J. Med., 1957;257:974-978	
	CC	Gajdusek and Zigas, Am. J. Med., 1959;26:442-469	
	CD	Prusiner et al., Prion Protein Biology, 1998;93:337-348	
	CE	Gerstmann et al., Z Neurol., 1936;154:736-762	
	CF	Ghetti et al., Proc. Natl. Acad. Sci. USA, 1996;93:744-748	
	CG	Ghetti et al., Mol. Neurobiol., 1994;8:41-48	
	CH	Medori et al., N. Eng. J. Med., 1992;326:444-449	
	CI	Goldfarb et al., Science, 1992;258:806-808	
	CJ	Collinge, Hum. Mol. Genet., 1997;6:1699-1705	
	CK	Collinge et al., Nature, 1996;383:685-690	
	CL	Collee and Bradley, Lancet, 1997;349:636-641	
	CM	Will et al., Lancet, 1997;347:921-925	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	Not Yet Assigned 10/558276
			Filing Date	Concurrently Herewith
			First Named Inventor	Thomas Wisniewski
			Art Unit	N/A
			Examiner Name	Not Yet Assigned
			Attorney Docket Number	05986/100M536-US1
Sheet	2	of	5	

	CN	Griffith, Nature, 1967;215:1043-1044	
	CO	Horwich and Weismann, Cell, 1997;89:499-510	
	CP	Prusiner, Science, 1982;216:136-144	
	CQ	Kretzschmar et al., Am. J. Pathol., 1986;122:1-5	
	CR	Pocchiari et al., J. Gen. Virol., 1987;68(Pt 1):219-223),	
	CS	Caughey and Race, J. Neurochem., 1992;59:768-771	
	CT	Ladogana et al., J. Gen. Virol., 1992;73(Pt 3):661-665	
	CU	Tagliavini et al., Science, 1997;276:1119-1122	
	CV	Soto et al., Lancet, 2000;355:192-197	
	CW	Priola et al., Science, 2000;287:1503-1506	
	CX	Aucouturier et al., Clin. Immunol, 2000;96:79-85	
	CY	Aucouturier et al., J. Clin. Invest., 2001;108:703-708	
	CZ	Wisniewski et al.Curr. Neurosci Reports 2002;2:400-4	
	CA1	Biochem. Soc. Transact. 2002;30:574-578	
	CB1	Sigurdsson et al., Am J Pathol 2002;161:13-17	
	CC1	Sigurdsson et al., Neurosci Lett, 2003;336:185-187	
	CD1	Steinberg, New Scientist, 2002; 16:22	
	CE1	Munch et al., J. Neural Transm., 2002;109:1081-1087	
	CF1	Schenk, Nat. Rev. Neurosci., 2002;3:824-828	
	CG1	White et al., Adv. Exp. Med. Biol., 1991;303:207-210	
	CH1	Lauterslager et al., Vaccine, 2003;21:1391-1399	
	CI1	Foss et al., Animal Health Research Reviews, 2000;1:3-24	
	CJ1	Sethi et al., Lancet, 2002;360:229-230	
	CK1	Mannino and Gould-Fogerite, Pharm. Biotechnol., 1995;6:363-87	
	CL1	Kaneko et al., J. Mol. Biol., 2000;295:997-1007	
	CM1	Peretz et al., Nature, 2001;412:739-743	
	CN1	E Cunha-Neto et al., PNAS, 1995;92:3541-3545	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Thomas Wisniewski
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	5	Attorney Docket Number	05986/100M536-US 1 1

10/558276

	CO1	E. Cunha-Neto et al., J. Clin. Invest., 1996;98:1709-1712	
	CP1	Chabalgoity et al., Vaccine, 2000;19:460-469	
	CQ1	Pasetti et al., Clin. Immunol., 1999;92:76-89	
	CR1	Hoiseth et al., Nature, 1981;291:238-239	
	CS1	Chatfield et al., Vaccine, 1992;10:53-60	
	CT1	Benkirane et al., J. Biol. Chem., 1993;268:26279-26285	
	CU1	Ben-Yedidia et al., Mol. Immunol., 2002;39:323-331	
	CV1	Ripka et al., Curr. Opin. Chem. Biol., 1998;2:441-452	
	CW1	Spatola, In: Chem. Biochem. Amino Acids, Pept., Proteins; Weinstein, B., Ed.; Marcel Dekker: New York, 1983; pp. 267-357	
	CX1	Hart and Rich, In: Pract. Med. Chem.; Wermuth, C., Ed., Acad. Press: London, U.K., 1996; pp. 393-412	
	CY1	Farmer, In: Drug Design; Ariens, E.J., Ed.; Academic Press: New York, 1980; 10:119-143	
	CZ1	Fletcher and Campell, Chem. Rev., 1998;98:763-795	
	CA2	Chabalgoity et al., Exp. Rev. Vaccines, 2002;1:495-505	
	CB2	Mastroeni et al., Veterinary Journal, 2001;161:132-164	
	CC2	Cardenas and Clements, Clin. Microbiol. Rev., 1992;5:328-342	
	CD2	Clements et al., 1992, In: Recombinant DNA Vaccines: Rationale and Strategy, Isaacson (ed.), Marcel Decker, New York. pp. 293-322;	
	CE2	Clements and Cardenas, Res. Microbiol., 1990;141:981-993	
	CF2	Sanitago et al., Pharmaceutical Research, 1993;10:1243-1247	
	CG2	Alving et al., Vaccine, 1986;4:166-172	
	CH2	Garcon and Six, J. Immunol., 1991;146:3697-3702	
	CI2	Gould-Fogerite and Mannino, 1993, In: Liposome Technology 2nd Edition. Vol. III, Gregoriadis (ed.)	
	CJ2	Mowat and Donachie, Immunology Today, 1991;12:383-385	
	CK2	Baylor, NW et al., Vaccine, 2002;20 Suppl 3:S18-23	
	CL2	Clements et al., Vaccine, 1988;6:269-277	
	CM2	Elson, Immunology Today, 1989;146:29-33	
Examiner Signature			Date Considered

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	Not Yet Assigned 10/558276
				Filing Date	Concurrently Herewith
				First Named Inventor	Thomas Wisniewski
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	5	Attorney Docket Number	05986/100M536-US 1

	CN2	Lycke and Holmgren, Immunology, 1986;59:301-308	
	CO2	Lycke et al., Eur. J. Immunol., 1992;22:2277-2281	
	CP2	Tamura et al., Japanese Journal of Infectious Diseases, 2000;53:98-106	
	CQ2	Finkelstein and LoSpalluto, J. Exp. Med., 1969;130: 185-202	
	CR2	Elson and Ealding, J. Immunol., 1984;133:2892-2897	
	CS2	Fujihashi et al., Acta Odontologica Scandinavica, 2001;59:301-308	
	CT2	Czerkinsky et al., Proc. Natl. Acad. Sci. (USA), 1989;57:1072-1077	
	CU2	Pierce et al., Infect. Immun., 1983;40: 1112-1118	
	CV2	Cebra et al., 1986, In: Vaccines 86, Brown et al. (ed.), Cold Spring Harbor Laboratory, New York. p.p. 129-133	
	CW2	McKenzie and Halsey, J. Immunol., 1984;133: 1818-1824	
	CX2	McCarthy et al., J. Immunol. Methods, 1985;82:349-358	
	CY2	McCarthy D.A. and Drake, A.F., Mol. Immunol., 1989;26(9):875-881	
	CZ2	Tacket et al., Infection and Immunity, 2000 Mar;68(3):1196-1201	
	CA3	Kotloff et al., Infect. Immun., 2002;70:2016-21	
	CB3	Lillard et al., Cellular and Molecular Biology, 2001;47:1115-1120	
	CC3	Levine et al., Journal of Biotechnology, 1996;44:193-196	
	CD3	Nardelli-Haeffliger et al., Infection and Immunity, 1996;64:5219-5224	
	CE3	Tacket et al., Infection and Immunity, 1997;65:452-456	
	CF3	O'Hagan et al. (Immunology 1991;73:239-42	
	CG3	Sigurdsson et al. (Am J Pathol 2001;159:439-447	
	CH3	Sobotka et al., Pharmacology, 1978;16:287-294	
	CI3	Quarternain et al., Neurosci. Lett., 2000;288:155-158	
	CJ3	Ammassari-Teule et al., Behav. Brain Res., 1985;17:9-16	
	CK3	Roullet et al., Physiol. Behav., 1998;64:203-7	
	CL3	Roullet et al., Physiol. Behav., 1995;58:1189-95	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

18 NOV 2005

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Thomas Wisniewski
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	05986/100M536-US ¹
Sheet	5	of	5		

10/558276

	CM3	Knobel et al., J. Wildl. Dis., 2002;38:352-62	
	CN3	Carp and Rubenstein, Semin. Virol 1991;2:203-213	
	CO3	Kascsak et al., J Virol, 1986;59: 676-683	
	CP3	Sigurdsson et al., TIMM, 2002;8:411-413	
	CQ3	Chabalgoity et al., Mol Microb., 1996;19(4):791-801	
	CR3	Clements and El-Morshidy, Infect. Immun., 1984; 46:564-569	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--